Anzeige
Mehr »
Login
Samstag, 18.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Letzte Chance, bevor die Bohrer dieses "Monster"-Vorkommen bei einem 13-Millionen-Unternehmen ansteuern
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
33 Leser
Artikel bewerten:
(0)

MentalHealth.com, LLC: MentalHealth.com Appoints Co-Founder Jeff Smith to Venture Advisory Team and Digital Operations

Finanznachrichten News

SAN FRANCISCO, CA / ACCESSWIRE / February 5, 2024 / Leading health technology company MentalHealth.com is pleased to announce the appointment of Jeff Smith to its Venture Advisory Team and as co-leader of digital operations.

MentalHealth.com

MentalHealth.com
MentalHealth.com Logo

The company's newly established Venture Advisory Team, comprised of seasoned business executives, accomplished tech entrepreneurs, and highly regarded healthcare professionals, works alongside leadership to drive business initiatives and uphold its people-first culture.

"Beyond his capacity as a proven digital strategist and marketing prodigy, Jeff Smith understands the challenges to mental well-being posed by the modern digital world," says Patrick Nagle, Co-Founder of MentalHealth.com. "His compassionate, heart-centered approach will be instrumental in developing resources and services that guide people towards self-understanding and connection."

Jeff Smith is a self-made entrepreneur, proven business leader, and accomplished healthcare founder. Alongside Co-Founder Abhilash Patel, he impressively led the rapid growth of San Diego-based Recovery Brands to its ultimate sale in 2015. Jeff Smith's journey began in homelessness as a child and has since led to the creation of industry-leading enterprises that consistently achieve annual organic traffic values exceeding $100M. His visionary leadership also played a pivotal role in facilitating M&A transactions totaling an impressive $220M. Jeff Smith has invested in more than 20 purpose-driven impact organizations, all aligned with his desire for a deeper understanding of ourselves, the world, and consciousness itself. Presently, Jeff Smith founded and co-led investments in Supermind Platforms, the driving force behind Psychedelics.com, where he proudly serves as CEO.

"As humanity struggles with disconnection and numbness, often seeking solace in substances and distractions, MentalHealth.com embarks on a crucial mission to support the well-being of billions worldwide," shared Jeff Smith. "I'm proud to stand with this exceptional team committed to seeking truth and practicing compassion. This is the path to a venture with meaning."

Jeff Smith joins previously announced appointees to the MentalHealth.com Venture Advisory Team, which includes Brian Trisler, Co-Founder of A Place for Mom, Fred Joyal and Gary Saint-Denis, Co-Founders of 1-800-DENTIST, and Abhilash Patel, Founder of Within Health. He will work alongside Co-Founder and Clinical Care Team Director, Dr. Jesse Hanson, PhD, and Public Oversight Committee Advisor, Ryan Hampton, with support from Co-Founder and CEO, Daniel Rivette.

About MentalHealth.com

MentalHealth.com is a health technology company guiding people towards self-understanding and connection. The company offers reliable resources, accessible services, and nurturing communities. Its mission involves educating, supporting, and empowering people in their pursuit of well-being.

Contact Information

Stacey Bartlett
pr@mentalhealth.com
1-800-834-8587

Related Files

MentalHealth.com - Jeff Smith, Venture Advisory Team.pdf
MentalHealth.com - Jeff Smith, Venture Advisory Team.txt

SOURCE: MentalHealth.com

.

View the original press release on newswire.com.

© 2024 ACCESS Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.